Oil Prices Slip as Middle East Tensions Ease, Heading for Weekly Loss 
Currency Markets Show Caution Amid U.S.-Iran Negotiations 
Gold Prices Drop Amid Iran Peace Talk Uncertainty and Stronger Dollar 
Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 
Iran-Israel Missile Strikes Continue Amid Mixed Signals on U.S.-Iran Diplomacy 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
U.S. Oil Prices Slide as Middle East Ceasefire Talks Spark Market Optimism 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Merck & Co. is said to be in advanced talks for the acquisition of Seagen, a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Fox Business reported that the acquisition deal could be valued at almost $40 billion. The amount could be more as the share price for Seagen is above $200 per share. The deal will help Merck & Co. with its expansion efforts as it adds a new acquisition to its cancer drug portfolio.
Currently, Merck’s highest-selling product is its Keytruda immunotherapy drug. The Rahway, New Jersey pharmaceutical company said that this drug accounted for $17.2 billion worth of its sales last year. As for Seagen, some of its best-selling products include Adcetris, which gathered total sales of $1.4 billion last year.
In any case, while Merck and Seagen are already in the advanced stage of negotiations, it was noted that there is still no assurance that they will be reaching an agreement for the sale of the latter.
Moreover, it was mentioned that any proposed deal in this negotiation is also expected to draw a close look from antitrust regulators. Both Merck and Seagen are still hoping to finally sign an agreement on or before Merck announces its second fiscal-quarter earnings, which has been scheduled for July 28.
Reuters reached out to Merck for comments regarding the acquisition reports, but it was not able to respond to the request immediately. On the other hand, Seagen was said to have declined to comment.
As of Wednesday, July 6, the companies are still discussing a price above $200 per share, and on that day, its closing share price was actually $175. It was added that Seagen has a market capitalization of $32.24 billion based on the records from Refinitiv data.
Meanwhile, industry observers believe that it will make sense if Merck & Co. is able to close its deal with Seagen for $250 or below. This is because this acquisition will definitely boost the company’s business and strengthen its portfolio through the latter’s exclusive cancer immunotherapy drug, Keytruda.
